NeuBase Therapeutics, Inc. reported earnings results for the second quarter ended March 31, 2023. For the second quarter, the company reported net loss was USD 4.09 million compared to USD 9.92 million a year ago. Basic loss per share from continuing operations was USD 0.12 compared to USD 0.3 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.378 USD | -3.20% | -6.67% | -48.93% |
Mar. 26 | Wall Street Set to Open Modestly Higher Tuesday Ahead Consumer Confidence Reading | MT |
Mar. 26 | US Futures Trend Higher Ahead of Durable Goods, House Prices, Consumer Confidence Readings | MT |
1st Jan change | Capi. | |
---|---|---|
-48.93% | 1.42M | |
+17.96% | 44.96B | |
+1.17% | 42.65B | |
+48.77% | 41.85B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- NBSE Stock
- News NeuBase Therapeutics, Inc.
- NeuBase Therapeutics, Inc. Reports Earnings Results for the Second Quarter Ended March 31, 2023